Patient Reported Outcomes
|
|
- Barnaby Spencer
- 5 years ago
- Views:
Transcription
1 Patient Reported Outcomes INTRODUCTION TO CLINICAL RESEARCH A TWO-WEEK INTENSIVE COURSE, 2010 Milo Puhan, MD, PhD, Associate Professor
2 Key messages Patient-reported outcomes (PRO) is a broad group of outcomes that directly reflect the patients perspective on symptoms, functional impairment and health-related quality of life Patient reported outcomes for comparative effectiveness research should be selected based on: Good responsiveness Established test-retest reliability Knowledge about their minimal importance difference Existing literature 2
3 What do patient report outcomes (PRO) measure?
4 Definition of patient-reported outcomes Information about a feature of health/disease that is obtained directly from the patient (with no interpretation by anyone else) 4
5 PROs: from simple to very complex measurements Multi-item Mutiple domains Measurement Complexity Pain Fatigue Symptom Index Physical Function Social Activities Health-related quality of life Activities of Daily Living Dyspnea during daily activities Pain during exercise Single Item Dyspnea when walking Abstractness of outcome
6 Patient-reported outcomes: Symptoms Uni-dimensional Dyspnea associated with physical activity Medical Research Council dyspnea scale Grade Degree of breathlessness related to activities 1 Not troubled by breathlessness except on strenuous exercise 2 Short of breath when hurrying or walking up a slight hill Walks slower than contemporaries on level ground because of breathlessness, or has to stop for breath when walking at own pace Stops for breath after walking about 100m or after a few minutes on level ground Too breathless to leave the house, or breathless when dressing or undressing 6
7 Patient-reported outcomes: Symptoms Multi-dimensional Dyspnea in different situations Chronic Respiratory Questionnaire dyspnea domain Extremely short of breath Very short of breath Quite a bit short of breath Moderate shortness of breath Some shortness of breath A little shortness of breath Not at all short of breath Not Done 1 Feeling emotional such as angry or upset 2 Taking care of your basic needs (bathing, showering, eating or dressing) 3 Walking 4 Performing chores (such as housework, shopping, groceries) 5 Participating in social activities Summary dyspnea domain score 7
8 Patient-reported outcomes: Health-related quality of life Security Symptoms Economy Health Quality of life Health-related quality of life Political stability Infrastructure Social environment Physical functioning Mental functioning Example: Mercer-Studies Example: SF-36 8
9 Patient-reported outcomes: Health-related quality of life Symptoms Pain Dyspnea Fatigue Physical functioning House keeping Walking Doing sports Health-related quality of life Mental functioning Depression Anxiety Questions do not address directly quality of life Abstract construct derived from underlying questions 9
10 Patient-reported outcomes: Health-related quality of life Uni-dimensional Please indicate on the scale from 0 to 100 how your health state was during last 7 days. Best imaginable health state Worst imaginable health state 5 Full health Death 10
11 Patient-reported outcomes: Health-related quality of life SF-36 8 domains Physical function 36 questions Role physical Bodily pain General Health Vitality Social function 2 summary scores Physical component score Mental component score Role emotional Mental Health 11
12 Patient-reported outcomes: Health-related quality of life Disease-specific instruments: Chronic Respiratory Questionnaire 4 domains Dyspnea 20 questions Fatigue Emotional function Mastery Total score 12
13 PROs: from simple to very complex measurements Multi-item Mutiple domains Measurement Complexity Pain Fatigue Symptom Index Physical Function Social Activities Health-related quality of life Activities of Daily Living Dyspnea during daily activities Pain during exercise Single Item Dyspnea when walking Abstractness of outcome
14 Development of PROs
15 The development of PROs is iterative
16 Is there a specific conceptual framework? A valid PRO should be based on a conceptual framework, which includes: What is the target population? What should be measured? Any disease? Specific disease? Disease severity? Clinical or general population? Symptoms? Functional impairment? Health-related quality of life? What s the purpose of the instrument? Treatment evaluation? Comparison of patients? Prediction of outcomes? evaluative discriminative predictive 16
17 The Chronic Respiratory Questionnaire Conceptual framework Disease: COPD Severity: Moderate to severe Concept COPD-specific healthrelated quality of life Population: Clinical Purpose: Evaluative Domains Dyspnea Emotional function Fatigue Mastery Items Dyspnea when doing chores Answer options: Likert-type 1-7 Scores: 1-7 per domain Recall period: 2 weeks 17
18 Steps in the development of PROs Conceptual framework A priori considerations Item and domain identification Item selection Questions Answer options Revision Adaptation Pilot testing Testing of measurement properties (validation) Translations Validation on other populations 18
19 Translation of PROs Testing of measurement properties (validation) Translations Forward Translation 1 Forward Translation 2 Professional interpreters Pilot testing Translated version1 Consensus meeting Professional interpreters Clinicians Methodologists Back translation Professional interpreter Revision Translated version 2 Validation Pilot testing 19
20 Measurement formats and properties
21 Reliability and validity Poor reliability and validity Good reliability but poor validity Good reliability and validity 21
22 Test-retest reliability First administration Typically 1-2 weeks) No change (treatments, exacerbations) Second administration r = 0.9 Intra-class correlation coefficient Between person variance Between + within person variance Inappropriate statistic Not bad, but does not correct for systematic differences Adequate 22
23 The validity challenge: No gold standard Face validity (expert knowledge) considered insufficient Known-group validity: Expected versus observed distributions Dyspnea Extreme Moderate No Mild Moderate Severe Severity of disease Construct validity: Expected versus observed correlations with external validation instruments 23
24 Construct validity: Expected versus observed correlations Instrument Chronic Respiratory Questionnaire Validation instruments Dyspnea Fatigue Mastery Emotional function MRC Dyspnea scale Self-reported physical activity Six-minute walk distance Exacerbations SF-36 physical functioning SF-36 mental functioning Hospital Anxiety and Depression Scale
25 Construct validity: Expected correlations Instrument Chronic Respiratory Questionnaire Validation instruments Dyspnea Fatigue Mastery Emotional function MRC Dyspnea scale Self-reported physical activity Six-minute walk distance Exacerbations SF-36 physical functioning SF-36 mental functioning Hospital Anxiety and Depression Scale High (>0.5) Moderate ( ) Moderate ( ) Moderate ( ) Moderate ( ) Low (<0.3) Low (<0.3) Moderate ( ) High (>0.5) Moderate ( ) Low (<0.3) Moderate ( ) Low (<0.3) Low (<0.3) Moderate ( ) Low (<0.3) Low (<0.3) High (>0.5) Low (<0.3) Moderate ( ) Moderate ( ) Low (<0.3) Low (<0.3) Low (<0.3) Moderate ( ) Low (<0.3) High (>0.5) High (>0.5)
26 Construct validity: Observed correlations Instrument Chronic Respiratory Questionnaire Validation instruments Dyspnea Fatigue Mastery Emotional function MRC Dyspnea scale 0.62 (>0.5) Self-reported physical activity 0.40 ( ) Six-minute walk distance 0.31 ( ) Exacerbations 0.38 ( ) SF-36 physical functioning 0.43 ( ) SF-36 mental functioning 0.20 (<0.3) Hospital Anxiety and Depression Scale 0.13 (<0.3) 0.43 ( ) 0.51 (>0.5) 0.44 ( ) 0.26 (<0.3) 0.47 ( ) 0.10 (<0.3) 0.11 (<0.3) 0.33 ( ) 0.21 (<0.3) 0.24 (<0.3) 0.47 (>0.5) 0.14 (<0.3) 0.54 ( ) 0.51 ( ) 0.15 (<0.3) 0.06 (<0.3) 0.22 (<0.3) 0.26 ( ) 0.09 (<0.3) 0.58 (>0.5) 0.81 (>0.5)
27 Responsiveness: Expected versus observed change Change expected First administration Second administration Treatment of known effectiveness Dyspnea Extreme No Baseline Follow-up Exacerbation (recovery) Dyspnea Extreme No Beginning Peak Exacerbations Recovery
28 Measures of responsiveness Treatment of known effectiveness Dyspnea Extreme No Baseline Follow-up Examples Comparison baseline and follow-up t-tests Wilcoxon Depends (too much) on sample size!! Cohen s effect size Mean change SD baseline Effect sizes Standardized response mean Mean change SD change 0.2 to <0.5 = small effect 0.5 to <0.8 = moderate effect 0.8 = large effect Many other measures 28
29 Generic vs. disease-specific instruments 281 COPD patients from four sites Respiratory rehabilitation of 12 weeks 179 patients at follow-up (102 lost because of SARS outbreak and other reasons) Generic instruments COPD-specific instruments SF-36 3 utility instruments Chronic Respiratory Questionnaire St. Georges Respiratory Questionnaire Resp Med 2007; 101,
30 Disease-specific instruments are more responsive COPD-specific instruments Standardized response mean CRQ, 4 domains SGRQ, 3 domains Generic instruments SF-36, 8 domains utility instruments Resp Med 2007; 101,
31 Conclusions responsiveness Look at responsiveness data Responsiveness disease-specific > disease-specific >> generic > generic 31
32 Minimal important difference
33 How should we interpret these data? Respiratory rehabilitation vs usual care for COPD Study Difference CRQ (95% CI) Simpson K ( ) Goldstein ( ) Güell ( ) Wijkstra PJ ( ) Cambach ( ) Hernandez MT ( ) Troosters T ( ) White ( ) Oh Eg ( ) Singh V ( ) Faager ( ) Combined 0.54 ( , p<0.001) favours usual care favours rehabilitation total score 33
34 The p-value is often not useful!! Imagine the following results Difference CRQ (95% CI) Combined 0.54 ( , p<0.001) Combined 0.44 ( , p<0.001) Combined 0.34 ( , p<0.001) Combined 0.24 ( , p=0.01) Combined 0.14 ( , p=0.05) Combined 0.04 ( , p=0.25) favours usual care favours rehabilitation total score We need a quantitative interpretation 34
35 The minimal important difference the smallest difference in the outcome of interest that informed patients or their proxies perceive as important and that may lead to a change in the management Related terms: Minimal clinically important difference (MCID) Clinically important difference Health services research 2005, 40(2):593 35
36 The MID of the CRQ is 0.5 Study Effects of inhaled drugs Difference CRQ (95% CI) Simpson K ( ) Goldstein ( ) Güell ( ) Wijkstra PJ ( ) Cambach ( ) Hernandez MT ( ) Troosters T ( ) White ( ) Oh Eg ( ) Singh V ( ) Faager ( ) Combined 0.54 ( , p<0.001) favours usual care favours rehabilitation total score 36
37 Methods to determine the MID Consensus-based Distribution-based Anchor-based Experts reach a consensus (e.g. Delphi methods) Statistical criteria: How strong is signal compared to noise Standardized response mean 0.5 Cohen s effect size 0.5 Standard error of measurement External instrument (anchor) with known MID used to estimate MID 37
38 MID of the Hospital Anxiety and Depression Scale in COPD patients Health and Quality of Life Outcomes 2008, 6:46 38
39 The HADS MID for COPD patients Between 1.41 and 1.68 with anchor-based method Between 1.17 and 1.40 with distribution-based method 1.5 on scale from 0-21 seems fair estimate Always use different methods since none of them is perfect 39
40 Use of the MID Interpretation of treatment effects for superiority AND non-inferiority trials Non-inferiority analysis for interval exercise trial Favours continuous exercise (n=41) CRQ Domain Favours Interval exercise (n=44) Difference Dyspnea 0.07 (-0.53 to 0.38) Fatigue 0.02 (-0.41 to 0.32) Emotional function 0.08 (-0.48 to 0.32) Mastery 0.01 (-0.42 to 0.45) Total score (-0.42 to 0.32) Differences between improvements Sample size calculations detection of important difference Annals of Internal Medicine 2006;145(11):816 40
41 Selection of PRO instruments
42 PROs: What are you interested in? Multi-item Mutiple domains Measurement Complexity Pain Fatigue Symptom Index Physical Function Social Activities Health-related quality of life Activities of Daily Living Dyspnea during daily activities Pain during exercise Single Item Dyspnea when walking Abstractness of outcome
43 43
44 Have standard steps for the development been followed? Conceptual framework A priori considerations Item and domain identification Item selection Questions Answer options Revision Adaptation Pilot testing Testing of measurement properties (validation) Translations Validation on other populations 44
45 Choice of patient-reported outcomes for CER Symptoms, functioning or health-related quality of life? Ideally matches measures of existing trials Meta-analysis! Can be measured reliably Responsive to change disease-specific instruments Established MID using valid methods Is reasonably efficient to measure (budget considerations) 45
46 Planning of a CER study in COPD Trial of rehabilitation in patients with COPD Our considerations Interested in health-related quality of life Matches measures of existing trials Can be measured reliably Responsive to change Established MID Efficient to measure MRC dyspnea scale SF-36 CRQ St Georges Resp Q 46
47 Planning of a CER study in COPD Trial of rehabilitation in patients with COPD Our considerations Interested in health-related quality of life Matches measures of existing trials MRC dyspnea scale SF-36 CRQ St Georges Resp Q /- + + Can be measured reliably +/ Responsive to change /- Established MID +/- +/- + + Efficient to measure + - +/- - 47
48 Key messages Patient-reported outcomes (PRO) is a broad group of outcomes that directly reflect the patients perspective on symptoms, functional impairment and health-related quality of life Patient reported outcomes for comparative effectiveness research should be selected based on: Good responsiveness Established test-retest reliability Knowledge about their minimal importance difference Existing literature 48
49 Further reading Streiner DL, Norman GR. Health Measurement Scales. Oxford University Press, 2003, 3rd edition. ISBN13: Journals: Health and Quality of Life Outcomes Journal of Clinical Epidemiology Quality of Life Research 49
Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life?
Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life? Summary of the evidence located: According to the NICE guideline on Chronic Obstructive Pulmonary Disease
More informationSelf-Management Plan for COPD
Self-Management Plan for COPD This is your personal management plan. The aim of this plan is to help you have better control of your chronic obstructive pulmonary disease (COPD). It will enable you to
More informationExercise in the management of breathlessness
WHO Collaborating Centre for Palliative Care and Older People Exercise in the management of breathlessness Matthew Maddocks PhD Lecturer in Health Services Research NIHR Clinical Trials Fellow Maddocks
More informationSelf-Management Plan for COPD
Self-Management Plan for COPD This is your personal management plan. The aim of this plan is to help you have better control of your chronic obstructive pulmonary disease (COPD). It will enable you to
More informationFatigue in COPD. Dr. Jan Vercoulen, Clinical Psychologist. Dpt. Medical Psychology Radboud University Nijmegen Medical Center
Fatigue in COPD Dr. Jan Vercoulen, Clinical Psychologist Dpt. Medical Psychology Radboud University Nijmegen Medical Center Definition COPD GOLD, 2016 Chronic Obstructive Pulmonary Disease = common preventable
More informationDevelopment of a self-reported Chronic Respiratory Questionnaire (CRQ-SR)
954 Department of Respiratory Medicine, University Hospitals of Leicester, Glenfield Hospital, Leicester LE3 9QP, UK J E A Williams S J Singh L Sewell M D L Morgan Department of Clinical Epidemiology and
More informationSelf-management plan for COPD
Sheffield Clinical Commissioning Group Sheffield Teaching Hospitals NHS Foundation Trust Self-management plan for COPD This is your personal management plan The aim of the plan is to help you have better
More informationSelf-Management Plan for COPD
Self-Management Plan for COPD This is your personal management plan. Bring it with you every time you see a nurse or doctor about your COPD The aim of this plan is to help you have better control of your
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationMULTICARE Health System Care of the Adult Chronic Obstructive Pulmonary Disease (COPD) Patient
Clinical Guideline Ver. 2.0 MULTICARE Health System Care of the Adult Chronic Obstructive Pulmonary Disease (COPD) Patient Target Audience: The target audience for this clinical guideline is all MHS providers
More informationA comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD
RESPIRATORY MEDICINE (2001) 95, 71 77 doi:10.1053/rmed.2000.0976, available online at http://www.idealibrary.com on A comparison of three disease-specific and two generic health-status measures to evaluate
More informationPatient reported outcomes in respiratory diseases; How to assess clinical success in COPD
Patient reported outcomes in respiratory diseases; How to assess clinical success in COPD Thys van der Molen, University of Groningen, Department of General Practice, The Netherlands Mr Valette Smoking
More informationSession 6: Choosing and using HRQoL measures vs Multi-Attribute Utility Instruments QLU-C10D and EQ-5D as examples
Session 6: Choosing and using HRQoL measures vs Multi-Attribute Utility Instruments QLU-C10D and EQ-5D as examples - Madeleine King & Richard De Abreu Lourenco- Overview Learning Objectives To discuss
More informationUsefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease
Thorax 1999;54:581 586 581 Academic Department of Respiratory Medicine, St Bartholomew s and Royal London School of Medicine and Dentistry, London Chest Hospital, London, UK EAPaul R Garrod R Garnham J
More informationPatient Assessment Quality of Life
Patient Assessment Quality of Life STEP 1 Learning objectives This module will provide you with an understanding of the importance of assessing Quality of Life (QoL) in patients and the role that quality
More informationPatient Reported Outcomes: are they appropriate for clinical practice? Jose M Valderas Clinical Lecturer
Patient Reported Outcomes: are they appropriate for clinical practice? Jose M Valderas Clinical Lecturer Key issues What are PROMs? Why PROMs? Assessing PROMs Interpreting PROMs Evidence for use in clinical
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationDevelopment and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire*
Original Research COPD Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire* Makiko Meguro, Mphil; Elizabeth A. Barley, PhD, CPsychol; Sally Spencer,
More informationReducing breathlessness through group singing
Reducing breathlessness through group singing Singing for Lung Health Impact Report February 2018 mt milestone tweed The singing helps you to expand your lungs and your life, it helps you to not limit
More informationPulmonary rehabilitation (PR) is an important
Power of Outcome Measurements to Detect Clinically Significant Changes in Pulmonary Rehabilitation of Patients With COPD* Juan Pablo de Torres, MD; Victor Pinto-Plata, MD; Edward Ingenito, MD; Peter Bagley,
More informationIntegrating a Plan of Action for Life
Reference Guide for Individual Patient Education Educational topics: Integrating a Plan of Action for Life 1. Prevention and management of COPD exacerbations Reasons for using an Action Plan and its structure
More informationInterpreting thresholds for a clinically significant change in health status in asthma and COPD
Eur Respir J 2002; 19: 398 404 DOI: 10.1183/09031936.02.00063702 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Interpreting thresholds for
More informationChapter 5: Patient-reported Health Instruments used for people with Chronic Obstructive Pulmonary Disease (COPD)
Chapter 5: Patient-reported Health Instruments used for people with Chronic Obstructive Pulmonary Disease (COPD) Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality
More informationNeuromuscular electrical stimulation for muscle weakness in adults with advanced disease
WHO Collaborating Centre for Palliative Care and Older People Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease Matthew Maddocks MCSP PhD NIHR Post-Doctoral Research
More informationHEALTH STATUS QUESTIONNAIRE 2.0
HEALTH STATUS QUESTIONNAIRE 2.0 Mode of Collection Self-Administered Personal Interview Telephone Interview Mail Other Patient: Date: Patient ID#: Instructions: This survey asks for your views about your
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More information호흡재활치료 울산의대서울아산병원 호흡기내과 이상도
호흡재활치료 울산의대서울아산병원 호흡기내과 이상도 Systemic (Extrapulmonary) effects in COPD Skeletal muscle dysfunction Osteoporosis Weight loss Sexual dysfunction Cardiovascular diseases (Gross et al., Curr Opin Pulm Med 2001;7:84)
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationDevelopment of a Conceptual Framework and Calibrated Item Banks to Measure Patient-Reported Dyspnea Severity and Related Functional Limitations
VALUE IN HEALTH 14 (2011) 291 306 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval Development of a Conceptual Framework and Calibrated Item Banks to Measure Patient-Reported
More informationThree triggers that suggest that patients could benefit from a hospice palliative care approach
Why is it important to identify people nearing the end of life? About 1% of the population dies each year. Although some deaths are unexpected, many more in fact can be predicted. This is inherently difficult,
More informationNational COPD Audit Programme
National COPD Audit Programme COPD: Who cares when it matters most? National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme: Outcomes from the clinical audit of COPD exacerbations admitted
More informationObjectives. Objectives. Definition. Physiology. Evaluation of the Dyspneic Patient. B. Celli Disclaimer
Evaluation of the Dyspneic Patient Bartolome R. Celli Harvard Medical School Brigham and Women s Hospital Boston B. Celli Disclaimer No stocks or ownership in any company. No Tobacco funds No promotional
More informationThe assessment of health status among patients with COPD
Eur Respir J 2003; 21: Suppl. 41, 36s 45s DOI: 10.1183/09031936.03.00078102 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2003 European Respiratory Journal ISSN 0904-1850 The assessment
More informationReference Guide for Group Education
A p l a n o f a c t i o n f o r l i f e Reference Guide for Group Education Session 5 Plan of Action: Part I Overview of the Plan of Action and Management of Respiratory Infections Plan of Action: Objectives
More informationNico Arie van der Maas
van der Maas BMC Neurology (2017) 17:50 DOI 10.1186/s12883-017-0834-1 RESEARCH ARTICLE Open Access Patient-reported questionnaires in MS rehabilitation: responsiveness and minimal important difference
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationNational COPD Audit Programme
National COPD Audit Programme COPD: Who cares when it matters most? National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme: Outcomes from the clinical audit of COPD exacerbations admitted
More informationo never o 1 day per week or less o 2-3 days per week o 4-6 days per week o every day
Quality of Life Questionnaire Qualeffo-41 (10 December 1997) Users of this questionnaire (and all authorized translations) must adhere to the user agreement. Please use the related Scoring Algorithm. A
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More informationInterpretation Clinical significance: what does it mean?
Interpretation Clinical significance: what does it mean? Patrick Marquis, MD, MBA Mapi Values - Boston DIA workshop Assessing Treatment Impact Using PROs: Challenges in Study Design, Conduct and Analysis
More informationComparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification
ORIGINAL ARTICLE COPD Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification Paul W. Jones 1, Lukasz Adamek 2, Gilbert Nadeau 2 and Norbert Banik 3 Affiliations:
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationPatient-Reported Outcomes (PROs) and the Food and Drug Administration Draft Guidance. Donald L. Patrick University of Washington
Patient-Reported Outcomes (PROs) and the Food and Drug Administration Draft Guidance Paul-Martini-Stiftung Berlin-Brandenburgische Akademie der Wissenschaften 6 March 2008 10:45 11:05 Donald L. Patrick
More informationFor each question you will be asked to fill in a bubble in each line: 1. How strongly do you agree or disagree with each of the following statements?
Appendix A: SF-36 Version 2 (modified for Australian use*) The SF-36v2 Health Survey Instructions for Completing the Questionnaire Please answer every question. Some questions may look like others, but
More informationCARE OF THE ADULT COPD PATIENT
CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationReference Guide for Group Education
A p l a n o f a c t i o n f o r l i f e Reference Guide for Group Education Session 1 Introduction to Living Well with COPD Education Program Participants Expectations Towards the Program Health in COPD
More informationChronic obstructive pulmonary disease in the Abertawe Bro Morgannwg area report IIb: COPD severity, flu vaccination and emergency admissions
Chronic obstructive pulmonary disease in the Abertawe Bro Morgannwg area report IIb: COPD severity, flu vaccination and emergency admissions 2012 Public Health Wales NHS Trust Material contained in this
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationHistory and Current State of PROs. Disclosures
1 History and Current State of PROs John Spertus MD MPH Professor of Medicine University of Missouri-Kansas City Disclosures Speaker s Bureaus: None Grant Support: ACCF, Abbott Vascular Consultant: United
More informationWhy use PROs? The relation to clinical outcomes
Introduction to Patient-Reported Outcomes (PROs) March 2-4 2004, Sigtuna, Sweden Why use PROs? The relation to clinical outcomes Olivier CHASSANY, MD, PhD Medical Manager, Clinical Research Dept (institutional
More informationThe Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference
1 NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust and Imperial College, Harefield, UK 2 Harefield Pulmonary Rehabilitation Unit, Royal Brompton & Harefield NHS
More informationSarcoidosis Registry Proforma
Patient Demographics Patient Data Has a patient consent form been completed? 1.1 Title Mr 1.2 1.3 Forename(s) PlainText Surname PlainText 1.4 Gender Male 1.5 1.6 1.7 1.8 1.9 Mrs Ms Miss Dr Other
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationCRITICALLY APPRAISED PAPER (CAP)
CRITICALLY APPRAISED PAPER (CAP) FOCUSED QUESTION In persons with chronic obstructive pulmonary disease (COPD), is a combination of exercise and activity-based breathing training more effective than a
More informationPatient Reported Outcomes (PROs) Tools for Measurement of Health Related Quality of Life
Patient Reported Outcomes (PROs) Tools for Measurement of Health Related Quality of Life David Victorson, Ph.D. Assistant Professor Department of Medical Social Sciences Northwestern University Feinberg
More informationThe COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study
1 St George s Hospital NHS Trust, London, UK 2 Guy s and St Thomas Foundation NHS Trust, London, UK 3 Greenwich Primary Care Trust, London, UK 4 Croydon Primary Care Trust, London, UK 5 The NIHR Respiratory
More informationChapter 2 A Guide to PROMs Methodology and Selection Criteria
Chapter 2 A Guide to PROMs Methodology and Selection Criteria Maha El Gaafary Introduction In general, medical management outcomes can be classified into clinical (e.g., cure, survival), personal (e.g.,
More informationPatient Follow-up Form - Version 1.1
Physician: [Last Name GO PROJECT Patient Follow-up Form - Version 1.1 Thank you for participating in the Glioma Outcomes Project. To continue participating in this important project, complete or correct
More informationResearch in Real Life Evaluation of patients with COPD and CKD who would benefit from aclidinium bromide treatment. Version Date: 15 th October 2013
Research in Real Life Evaluation of patients with COPD and CKD who would benefit from aclidinium bromide treatment. Version Date: 15 th October 2013 Draft protocol Characterising patient groups with chronic
More informationThe EuroQol and Medical Outcome Survey 36-item shortform
How Do Scores on the EuroQol Relate to Scores on the SF-36 After Stroke? Paul J. Dorman, MD, MRCP; Martin Dennis, MD, FRCP; Peter Sandercock, MD, FRCP; on behalf of the United Kingdom Collaborators in
More informationOutpatient Pulmonary Rehabilitation
Outpatient Pulmonary Rehabilitation Policy Number: 8.03.05 Last Review: 7/2018 Origination: 7/1995 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationHow to incorporate Patient- Reported Outcomes (PROs) in Cochrane reviews? Caroline Terwee, Donald Patrick, Gordon Guyatt, Riekie de Vet
How to incorporate Patient- Reported Outcomes (PROs) in Cochrane reviews? Caroline Terwee, Donald Patrick, Gordon Guyatt, Riekie de Vet Aim of the workshop To provide some guidelines for how PROs can be
More informationQualitative Methods and Patient Reported Outcome Measures. Susan C Pitt, MD, MPHS Assistant Professor of Surgery University of Wisconsin
Qualitative Methods and Patient Reported Outcome Measures Susan C Pitt, MD, MPHS Assistant Professor of Surgery University of Wisconsin Disclosures None Overview What is it? When is it useful? Why do it?
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationDivision of Pulmonary, Critical Care, and Sleep Medicine, Jacksonville, FL. Department of Internal Medicine, Wichita, KS
in Patients with Respiratory Disease Furqan Shoaib Siddiqi, M.D. 1, Said Chaaban, M.D. 2, Erin Petersen, M.S.N., A.P.R.N. 3, K James Kallail, Ph.D. 2, Mary Hope, B.H.S., A.R.T., R.R.T., C.P.F.T. 3, Daniel
More informationMedical Standards for Actigraphy
Medical Standards for Actigraphy Gemeinsame Jahrestagung SGK, SGHC & SGP Lausanne, 17.6. 2016 Milo Puhan, MD, PhD Chair of Epidemiology & Public Health, Director EBPI Seite 1 Key questions Why do we want
More informationInterventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600
Endobronchial valve insertion to reduce lung volume in emphysema Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600 Your responsibility This guidance represents
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPlease return the questionnaire in the enclosed pre-paid envelope
Instructions Please complete the questionnaire, making sure you reply to all the questions. This should take you about 20 minutes. If you have difficulties completing the questionnaire, please ask someone
More informationOutpatient Pulmonary Rehabilitation
Outpatient Pulmonary Rehabilitation Policy Number: 8.03.05 Last Review: 7/2017 Origination: 7/1995 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationEndobronchial valve insertion to reduce lung volume in emphysema
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Endobronchial valve insertion to reduce lung volume in emphysema Emphysema is a chronic lung disease that
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/28958 holds various files of this Leiden University dissertation Author: Keurentjes, Johan Christiaan Title: Predictors of clinical outcome in total hip
More informationHealth and Quality of Life Outcomes BioMed Central
Health and Quality of Life Outcomes BioMed Central Guidelines Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance U.S.
More informationThe Five Facet Mindfulness Questionnaire
The Five Facet Mindfulness Questionnaire Mindfulness Questionnaire 8-10 min. Client The Five Facet Mindfulness Questionnaire (FFMQ; Baer, Smith, Hopkins, Krietemeyer, & Toney, 2006; Baer et al., 2008)
More informationPatient Reported Outcomes in Arthritis, TJR, and Physical Activity Research
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2016 UMass Center for Clinical and Translational Science Research Retreat
More informationDiscussion and Personal Reactions:
INSTRUCTIONS FOR THE PRECEPTOR Please assign the students a patient to meet and interview, there can be 3-4 students/patient not necessarily 1:1 Patient should preferably be living with advanced illness
More informationChronic Obstructive Pulmonary Disease (COPD) is a systematic disease with
Chronic Obstructive Pulmonary Disease (COPD) is a systematic disease with considerable impact on several dimensions of daily life. Those that suffer from COPD can be submitted to rehabilitation programmes.
More informationGOLD UPDATE on COPD and the Importance of Accurate Dyspnea Evaluation
GOLD UPDATE on COPD and the Importance of Accurate Dyspnea Evaluation George Anderson, PhD Sr. Medical Science Liaison MA-AZAP ML-4006-US-0212 Approved 11/16 Glob al Strategy for the Diagnosis, Management,
More informationCardiac & Pulmonary Rehab Individual Treatment Plan
Initial Assessment Date: Re-Assessment Date: Re-Assessment Date: Follow-Up Discharge Date: Risk Assessment Risk Assessment Risk Assessment Risk Assessment BP SpO2 BP SpO2 BP SpO2 BP SpO2 HR Edema HR Edema
More informationPsychometric properties of the Chinese quality of life instrument (HK version) in Chinese and Western medicine primary care settings
Qual Life Res (2012) 21:873 886 DOI 10.1007/s11136-011-9987-3 Psychometric properties of the Chinese quality of life instrument (HK version) in Chinese and Western medicine primary care settings Wendy
More informationNews on Evidence-Based Care Fourth Quarter 2013 Volume 5 Issue 4
SPECIAL EDITION: COPD CME AVAILABLE! News on Evidence-Based Care Fourth Quarter 2013 Volume 5 Issue 4 Update on Chronic Obstructive Lung Disease (COPD) 2013 During 2013, the Institute for Evidence-Based
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION Macitentan (Opsumit Actelion Pharmaceuticals Canada Inc.) Indication: Pulmonary Arterial Hypertension Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that
More informationCHAPTER - III METHODOLOGY
74 CHAPTER - III METHODOLOGY This study was designed to determine the effectiveness of nurse-led cardiac rehabilitation on adherence and quality of life among patients with heart failure. 3.1. RESEARCH
More informationQuality of Life after. A Critical Illness: A review of the literature
1 Quality of Life after A Critical Illness: A review of the literature 1998 2003 by Harriet Adamson BN MAdEd A Thesis submitted in fulfillment of the requirements for the degree Master of Nursing (Honours)
More informationLIST CHANGES IN YOUR MEDICATION OR SUPPLEMENTS INTAKE (add new meds, changes in old meds or meds you stopped taking) Are you taking it?
Date Patient name: LIST YOUR THREE MAIN COMPLAINTS FOR THIS VISIT - - - New med Old med LIST CHANGES IN YOUR MEDICATION OR SUPPLEMENTS INTAKE (add new meds, changes in old meds or meds you stopped taking)
More informationChronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
More informationExercise Rehabilitation and Chronic Obstructive Pulmonary Disease Stage
Exercise Rehabilitation and Chronic Obstructive Pulmonary Disease Stage MICHAEL J. BERRY, W. JACK REJESKI, NORMAN E. ADAIR, and DANIEL ZACCARO Department of Health and Exercise Science, Department of Public
More informationThey Can t Bury You while You re Still Moving: Update on Pulmonary Rehabilitation
They Can t Bury You while You re Still Moving: Update on Pulmonary Rehabilitation Richard ZuWallack, MD Associate Chief, Pulmonary and Critical Care St. Francis Hospital, Hartford, CT Professor of Medicine
More informationNAME OF PATIENT: STREET ADDRESS: CITY: STATE: ZIP: SEX: Male Female AGE: BIRTHDATE: MARITAL STATUS: PATIENT EMPLOYED BY: BUSINESS ADDRESS:
DATE: HOME PHONE: NAME OF PATIENT: (Last name) (First name) (Middle) RESPONSIBLE PARTY (if a minor): STREET ADDRESS: CITY: STATE: ZIP: SEX: Male Female AGE: BIRTHDATE: MARITAL STATUS: PATIENT EMPLOYED
More informationDr Dimitra Nikoletou Associate Professor- Faculty of Health, Social Care and Education, Kingston and St George s University of London.
Are there differences in adherence to home-based, inspiratory muscle training programmes between athletes and non-athletes? Implications for designing community based rehabilitation programmes for respiratory
More informationSpecialist Palliative Care Referral for Patients
Specialist Palliative Care Referral for Patients This guideline covers referrals for patients with progressive terminal illness, whether due to cancer or other disease. For many patients in the late stages
More informationMaking a psychometric. Dr Benjamin Cowan- Lecture 9
Making a psychometric Dr Benjamin Cowan- Lecture 9 What this lecture will cover What is a questionnaire? Development of questionnaires Item development Scale options Scale reliability & validity Factor
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More information1. Evaluate the methodological quality of a study with the COSMIN checklist
Answers 1. Evaluate the methodological quality of a study with the COSMIN checklist We follow the four steps as presented in Table 9.2. Step 1: The following measurement properties are evaluated in the
More informationPlease complete ALL 6 pages of the form in blue/black ink. Patient Acct # Provider # BMI # Height Weight
Please complete ALL 6 pages of the form in blue/black ink. Patient Acct # Provider # BMI # Height Weight f-25-n (08-07-13) ( 11-02-12) 0 10 Spine Questionnaire (continued) OFFICE USE ONLY Patient Acct
More informationSleep Health Center. You have been scheduled for an Insomnia Treatment Program consultation to further discuss your
Sleep Health Center You have been scheduled for an Insomnia Treatment Program consultation to further discuss your sleep. In the week preceding your appointment, please take the time to complete the enclosed
More information